Filing Flows › Rhythm Pharmaceuticals (RYTM) › Q2 2025
Rhythm Pharmaceuticals (RYTM) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 5, 2025
Rhythm Pharmaceuticals (RYTM) reported revenue of $48.5M for the second quarter 2025 (Q2 2025), +67% from a year earlier and +48% from the quarter before. Operating margin was -93.4%, net loss $46.6M (96.1% of revenue).
Rhythm Pharmaceuticals, Q2 2025: revenue $48.5M (+67% year over year), operating margin -93.4%, net loss $46.6M, operating cash flow −$23.3M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $48.5M | +48% | +67% |
| Operating profit | −$45.3M | — | — |
| Net earnings | −$46.6M | — | — |
| Operating cash flow | −$23.3M | — | — |
What changed
Revenue was $48.5M in Q2 2025, up 67% year over year and up 48% from the previous quarter.
Operating costs exceeded revenue by $45.3M, an operating margin of -93.4%. Total costs grew 35% against revenue growth of 67%. The fastest-growing cost line was Cost of revenue (+88%). The quarter ended with a net loss of $46.6M, narrower than the previous quarter's $49.5M loss.
Operating cash flow was −$23.3M. Non-cash charges added back $15.9M of share-based compensation. Working capital and other items added $7.4M.
Questions
What was Rhythm Pharmaceuticals' revenue in the second quarter 2025?
Rhythm Pharmaceuticals (RYTM) reported revenue of $48.5M for the second quarter 2025 (Q2 2025), +67% from a year earlier and +48% from the quarter before.
Was Rhythm Pharmaceuticals profitable in the second quarter 2025?
Operating loss was $45.3M (-93.4% of revenue) and net loss $46.6M.